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Abstract. – In Type 1 Diabetes (T1D) in chil-
dren, close to the onset the requirements of in-
sulin are often reduced. This represents a tran-
sient recovery of endogenous insulin secretion 
named “honeymoon” because transient and fol-
lowed by a progressive decline in C-peptide se-
cretion. This case report describes the effect of 
administration of high dose vitamin D and Ω-3 
fatty acids on T1D progression in a 8-year-old 
child. At today after one year and a half from the 
onset of T1D, the subject shows a near-normal 
blood glucose with the administration of 1.5-2 UI 
of insulin once a day. Thus this report may be 
of assistance to design additional studies to de-
termine and validate the effect of administration 
of vitamin D and Ω-3 fatty acids on the progres-
sion of T1D
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Introduction
Following the onset of Type 1 Diabetes (T1D) 
in children, the initial requirements for exog-
enous insulin therapy to reverse keto-acidosis 
and stabilize blood glucose levels, are generally 
substantially reduced. This partial remission is 
named the “honeymoon” phase and represents 
a transient recovery of endogenous insulin se-
cretion (REIS). The “honeymoon” phase usually 
occurs shortly after T1D diagnosis, but is tran-
sient in nature and could last weeks to several 
months and even over one year, during which a 
progressive decline in C-peptide secretion is usu-
ally observed. The decline in endogenous insulin 
production is generally more severe in young-
er children compared to adolescents and young 
adult subjects. Additional factors contribute to 
determine the endogen insulin decrease and the 
autoimmune process progressively decreasing 
and virtually eliminating any significant resid-
ual insulin secreting β cells mass in subsequent 
years. A goal of diabetes care is to maintain meta-
bolic control, stabilizing blood glucose levels and 
minimizing glycemic variability, to decrease the 
risk of hypoglycemia and development of compli-
cations of the disease in the following decades. In 
this direction preservation of even residual β-cell 
mass would be highly desirable1,2. The autoim-
mune mediated apoptosis of β-cells represents the 
underlying process both of T1D onset and relapse 
of insulin needs, whose correspondent histology 
is an infiltration of neutrophils, T-lymphocytes 
and peripheral blood mononuclear cells into the 
pancreatic islets named “insulitis”. Several cy-
tokines are involved as mediators of inflamma-
tion3,4, Vitamin D and Ω-3 and Ω-6 fatty acids 
are hypothesized to play a role in those complex 
events as immune modulators and as agonists or 
antagonist of inflammation5-7. 
The usual definition honeymoon is when close 
to the onset the need of insulin is less than 0.5 
IU/ kg/day, to assume the metabolic control is 
achieved with significantly REIS.
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This case report describes the effect of admin-
istration of high dose vitamin D and Ω-3 fatty 
acids on T1D progression in a 8-year-old child. 
At today after one year and a half from the onset 
of T1D, the subject shows a near-normal blood 
glucose with the administration of 1.5-2 UI of 
insulin once a day. Thus this report may be of 
assistance to design additional studies to deter-
mine and validate the effect of administration of 
vitamin D and Ω-3 fatty acids on the progression 
of T1D.
Case Report
The subject is the first-born child in a family 
without a history of T1D, only the paternal grand-
mother referred Type 2 Diabetes and a sister one 
year and a half younger is gluten intolerant. At 
the age of 7 years and 4 months, he had the clas-
sic symptoms of diabetes (thirst, hunger, weight 
loss and copious urination during day and night), 
which after ten days led him to the hospital on 
November 21, 2015, after his mother detected glu-
cose in urine through a stick test. At the arrival 
he was healthy, the blood glucose was 227 mg/dl, 
and EGA was normal (pH 7.4, pO2 146 mmHg, 
[HCO3] 17.4 mmol/L). The weigh was kg 24, and 
high 127 (respectively 50° and 75° Italian child-
hood percentiles). 
During hospitalization the balance has been 
easy achieved with MDI, with Lys-pro and in-
sulin glargine, progressively reduced from 0.7 
to 0.37 IU/Kg/die at the discharge five days 
later. There were found genetic phenotype DQ2-
DR3 (corresponding to DQA1* 05:01, DQB1* 02:01, 
DRB1* 03), and specific autoimmunity pattern 
of T1Da [GAD 22.4 IU/ml (n.v. <1.0), IA-2 0.90 
IU/ml (n.v. <0.70), IAA 0.30 IU/ml (n.v. 0.00-0.40) 
and ZnT8 162 UA/ml (n.v. <15)], none for CD 
[Transglut-A 2.9 CU (n.v. 0-20), Antigliadin-dm 
Ab IgA 2.5 CU (n.v. 0-20), IgG 3.2 CU (n.v. 0-20)] 
and partial against thyroid [Ab TPO 71 IU/ml (n.v. 
0-60), Ab TRG < 30 IU/ml (n.v. 0-60)] with normal 
TSH [2.932 µIU/ml (n.v. 0.45-3.50)] and fT4 [1.55 
ng/dl (n.v. 0.89-1.76)]. Blood count (Neutrophil 
leukocytes 6816 mm3), electrolytes, transami-
nases, amylase and lipase were normal. Serum 
creatinine was normal (0.43 mg/dl). Notably at 
onset HbA1c was 9.6% (120 mmol/l). C-peptide 
was 0.5 ng/ml (n.v. 0.8-4.2), with a C-peptide/Glu-
cose ratio of 0.42 (Glucose level of 120 mg/dl at the 
time of C-Peptide sample). Vitamin D [25(OH)
D3] was 25.9 ng/ml. 
After discharge the metabolic control of the 
child was optimal, but a month later overcoming 
hypoglycemia entailed a rapid decrease of insulin 
needs (from 0.37 to 0.08 IU/kg/day). Especially the 
need for insulin for meals decreased and Lys-Pro 
was removed, while a relatively higher awakening 
blood glucose advised to keep a dose of glargine 
1.5 IU/die at bedtime. Insulin glargine average 
dose was 1.5 IU/die (dosages 1, 1.5, 2 IU/day, ac-
cording to the previous blood glucose on awaken-
ing, <110, 111-119, >120 mg/dl). The glycosylated 
hemoglobin rapidly fell near normal. The reduced 
glycemic variability confirmed the REIS and 
metabolic stability. The child always presented 
regular weight gain and normal BMI. Data are 
summarized in Table I, mean blood glucose and 
DS are shown in Figure 1.
The overall picture of blood sugar levels is 
deductible by the discharge of the meter (Con-
turnext USB® Ascensia Diabetes Care) and is 
summarized in Figure 1. DS are detailed before 
three meals. 
Table I A. Auxological and metabolic parameters.
*C-peptide (ng/mL)/glucose (mg/dL) x100. Assessed in fasting or in postprandial state (2 h)
Time (born Age BMI HbA1c% Blood Insulin C-peptide C-peptide/ 
 5/07/2008) (ys) (kg/m2) (mmol/mol) glucose needs (ng/ml) Glucose
    (mg/dL) (IU/kg/d)  ratio*
T. 0 (onset 11/22/15) 7ys 4m 15 9.6 (82.0) 120 0.39 0.5 0.41
  (25.5/1.32)
T. 1 (04/06/16) 7 ys 9m 14.4 6.0 (42.0)  0.08
  (25/1.322)   
T. 2 (09/14/16) 8ys 2m 14.4 5.7 (39.0) 84 0.04 0.5 0.59
  (26//1.352)
T. 3 (02/12/17) 8ys 7m 14.9 6.2 (45.0)  0.05
  (27.5/1.362)   
T. 4 (03/13/17) 8ys 8m  5.8 (40.0) 98 (fasting) 0.05 0.6 (fasting) 0.61 (fasting)
    102 (post meal)  1.6 (post meal) 1.56 (post meal)
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When was programmed tonsillectomy further 
investigations were C-peptide/Glucose ratio (0.61 
before breakfast, increased to 1.56 after that), 
lipid profile (showing low triglycerides. Total 
cholesterol 163, HDL 74, LDL 82 mg/dl, and 
triglycerides 35 mg/dl) and coagulation (normal, 
PT-INR 1.06, PT 12.2”, PT ratio 1.07). Additional 
subcutaneous glucose monitoring was arranged 
for the short period close to tonsillectomy (see 
additional FGM with FreeStyle Libre® Abbott).
At discharge, it was indicated vitamin D ther-
apy at a dose of 1000 IU/day until today, and 
subsequently undertaken the administration of 
highly purified Ω-3 fatty acids at a dose of 55-60 
mg/kg/day, divided into three doses a day (T.1). 
Average daily supplementation was DHA 500 mg 
EPA 1000 mg. The intake of Ω-3 EPA and DHA 
had been finalized to point AA/EPA ratio <3, 
referred as optimal8,9, and vitamin D supplemen-
tation as cholecalciferol, to obtain a concentration 
of 25(OH)D3 in the range 30-50 ng/dl.
Whole blood fatty acid composition was de-
termined three times: at baseline (T.1), after five 
(T.2) and ten months (T.3) to monitor Ω-3 and 
Ω-6 percentages of fatty acids in the venous blood 
(Table III). At T.3 a dietetic assessment of the 
food intake was performed on the basis of a food 
diary from 5 different days. A further interview 
with a dietitian was done with parents to evaluate 
the macro and micronutrients intake of food as 
precise as possible. The amounts of the various 
nutrients have been developed with the support of 
the Food Composition Database for Epidemiolog-
ical Studies (BDA version 1-2015). Were evaluat-
ed protein (g/day), energy (Kcal/day), cholesterol 
(mg/day), simple carbohydrates (g/day), dietary fiber 
(g/day) calcium (mg/day), sodium (g/day), potassium 
(g/day), vitamin D (g/day), vitamin K (mg/day), 
polyunsaturated fatty acids (g/day), arachidonic 
acid (AA g/day), EPA (g/day) and DHA (g/day). 
Intake of AA, EPA and DHA are summarized in 
Table II. The diet analysis is reported in Table IV.
Discussion
Throughout the period considered, the level 
of child’s growth was normal, with a weight 
gain of 2 kg in 1 year and a half, and wasn’t 
reported particular problems, with excellent ac-
ceptance of the supplementation. The intake of 
Ω-3 capsules was performed in three times a 
day without any swallowing difficulty. Even the 
diet through a particular skill of the mother in 
the selection and preparation of the food was 
well-accepted. The gluten intolerance of the sis-
ter resulted in a virtually gluten free diet for him 
as well. In the diaries, only 3% of glucose values 
Table I B. Blood glucose mean values from the meter.
Year/ month, Average blood glucose Average blood glucose Average blood glucose
 n. test wake up (DS) mg/dl lunch (DS) mg/dl dinner (DS) mg/dl
2015/ 11-12, test 234 166 (52) 123 (40) 123 (48)
2016/ 01-12, test 1538 104 (27) 95 (22) 116 (30)
2017/ 01-03, test 228 119 (10) 88 (18) 121 (38)
Figure 1. Mean blood glucose levels (mean±SD) pre and 
post breakfast, lunch and dinner during the months.
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were over and 8% under the recommended blood 
glucose target (respectively >180 and <70 mg/
dl), and in the last three months 1% over, and 
12% under target (see Figure 2). A few hypo-
glycemic episodes were reported during the first 
month of insulin treatment; then, the therapy 
was corrected reducing insulin doses. None 
hypoglycemia was severe requiring assistance 
or glucagon. Occasional single elevated blood 
sugar levels are reported, especially during in-
tercurrent inflammations of the upper airways. 
Surprisingly without administrations of insulin, 
the blood glucose spontaneously returned to the 
normal range within 2-3 hours. Even during a 
tonsillectomy, there was one episode of hyper-
glycemia and later in the post-surgical observa-
tion hypoglycemia with spontaneous resolutions 
and without insulin nor intravenous glucose 
administration, only two packets of sugar were 
dispensed when blood glucose decreased below 
50 mg/dl. The rapid recovery of normal blood 
glucose concentrations after occasional hyper-
glycemia suggests a substantial persistence of 
β-cell mass. Also, the absence of hypoglycemia 
when insulin dosage was stabilized with 1-2 IU 
glargine at evening, strongly argues for endog-
enous insulin production. The higher average 
blood glucose and increased variability in the 
wake reflect the physiologic circadian rhythm 
of insulin sensibility with downregulation in 
the early morning. Moreover, the persistence of 
C-peptide levels ≥ 0.5 ng/ml is the direct evi-
dence of REIS over time, and comparing with 
fasting blood glucose measured simultaneously 
Table II. Supportive and nutritional therapies.
 AA intake EPA+DHA Supplementation Vit. D EPA % DHA % AA/EPA
 mg/d intake mg/d EPA+DHA mg 25(OH)D3 fatty fatty
 in diet in diet mg/kg/d ng/ml acids acids
    
T. 0 (onset    25.9
 11/21/15)    Start point
    1000UI VitD
T. 1 (04/06/16)   0  0.396 2.792 33.674
   59   
T. 2 (09/14/16)   1500 38.3 3.128 1.839 2.270
   60 
T. 3 (02/12/17) 392 349 + 661 1500 41.8 3.541 3.940 2.971
   54.5 
Table III. Blood fatty acid composition.
Whole blood fatty acid composition was determined on 
a droop of venous blood collected by the family at home 
by fingerstick and deposited on absorbent paper treated 
with BHT. This method allows easy sample shipment 
to the analytical laboratory, without deterioration of 
Polyunsaturated fatty acids (Rizzo et al. Lipids in Health 
and Disease 2010; 9: 7).
% Fatty acid      PRE +5 Months +1 Year
C16:0  25.386  21.900  18.694 
C16:1  0.530  2.106  0.899 
C18:0  9.607  14.988  10.915 
C18:1  19.721  24.080  27.205 
C18:2  25.773  21.350  20.188 
α C18:3  0.118  0.635  0.691 
γ C18:3  0.960  1.572  0.688 
C20:3  0.753  0.766  1.066 
C20:4 (AA) 13.325  7.101  10.521 
C20:5 (EPA) 0.396  3.128  3.541 
C22:5 (DPA) 0.639  0.536  1.651 
C22:6 (DHA) 2.792  1.839  3.940 
SFA 34.993  36.888  29.608 
MUFA 20.251  26.186  28.104 
PUFA 44.756  36.926  42.287 
OMEGA-6  40.811  29.851  32.464 
OMEGA-3  3.945  7.075  9.824 
OMEGA-6/OMEGA-3 10.346  4.219 3.305
AA/EPA 33.674 2.270  2.971
Table IV. Nutrients daily intake.
Nutrients Daily intake
Protein (g) 89
Energy (kcal) 2005
Soluble carbohydrates (g) 54.7
Dietary fiber (g) 19.3
Calcium (mg) 709.8
Sodium (mg) 1216
Potassium (mg) 2413
Vitamin D (µg) 8.94
Vitamin K (µg) 0.81
AG polyunsaturated (g) 22.83
Arachidonic acid (g) 0.392
EPA (g) 0.349
DHA (g) 0.661
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it states an adequate steady basal insulin se-
cretion (C-peptide/Glucose ratio slightly raised 
from 0.5 to 0.6 ng/ml, from T.0 to T4). Finally, 
at T.4 the measurement of C-peptide stimulated 
by a meal provides an adequate β-cell mass to 
control blood sugar levels in post-prandium11. 
Undoubtedly the carefully adopted high fiber 
diet that minimized high glycemic index foods 
could have contributed to the limited elevation 
of blood glucose levels after meals. The glu-
ten-free diet does not usually reduce insulin 
requirements, but we don’t exclude it may play 
a role in the modulation of inflammation and 
autoimmunity. Even during surgical stress both 
the capillary blood glucose and the interstitial 
glucose recorded confirmed a substantial auton-
omous capacity of the subject’s blood glucose 
control (Figure 2).
Nevertheless, the exceptional clinical course 
observed in this child, “honeymoon” phase 
strongly suggests a possible role of vitamin D 
and Ω-3 supplemental administration. The ad-
ministration of Ω-3 fatty acids has been reported 
to suppress synthesis of interleukin-1β (IL-1 β) 
and tumor necrosis factor, and vitamin D has 
been associated with immunomodulation and en-
hancement of regulatory T-cells function.
The rapid decline of β-cell function after the 
diagnosis of T1D is a paradigm that could be 
revisited today, since recent evidence shows that 
it is possible to delay progression of the disease. 
In fact, recent findings from TrialNet describe a 
detectable C-peptide in 93% of patients 2 years 
after diagnosis, and ongoing trials are testing 
immunosuppressive drugs that could have an 
effect on the progression of autoimmunity12,13. 
Nevertheless, maintenance or improvement of 
fasting C-Peptide 15 months after T1D onset has 
never been reported in young children below age 
9. Unfortunately, the robust data on C-peptide 
secretion obtained in adults cannot be transferred 
to younger children, which have a different insulin 
secretion and many rapid patterns of C-Peptide 
disappearance following T1D onset. Furthermore, 
the immunosuppressive drugs used in adult inter-
vention trials aren’t always advisable for children 
because of their toxicity and side effects. Thus, the 
identification of potentially effective “safe ther-
apies” is of particular interest, as it would allow 
for the broader inclusion of children in adequate 
prevention trials. These findings support the posi-
tive results of previous publications on the effect of 
high dose Ω-3 and Vitamin D on modulation of in-
flammation and immunity in autoimmune disease 
conditions, including T1D13,14. Recently a synergy 
between vitamin D and Ω-3 has been found also 
in a randomized study of pregnant women with 
gestational diabetes lowering the blood glucose 
and improving the insulin sensitivity15.
Conclusions
This case report supports the concept that 
co-administration of high dose vitamin D and Ω-3 
fatty acids could represent a safe and cost-effec-
tive strategy that may be of assistance to halt the 
progression of Type 1 Diabetes. These findings 
should be confirmed by randomized prospective 
trials and could be of assistance to define novel 
strategies for immune interventions in other auto-
immune disease conditions.  
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Figure 2. Interstitial glucose 
levels before and after tonsil-
lectomy (March-20-2017).
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